RecruitingPhase 1NCT05287568

CC-486 and Venetoclax for Acute Myeloid Leukemia

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Colorado, Denver
Principal Investigator
Daniel E Pollyea, MD
University of Colorado, Denver
Intervention
Venetoclax(drug)
Enrollment
35 enrolled
Eligibility
18-100 years · All sexes
Timeline
2022 – 2029

Study locations (2)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05287568 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials